UJVIRA 100 mg is an antibody–drug conjugate combining the HER2-targeting power of trastuzumab with the microtubule inhibitor DM1. By binding selectively to HER2 receptors, it delivers chemotherapy inside cancer cells while sparing healthy tissue—improving outcomes for patients whose tumors overexpress HER2 protein.
Key Features & Benefits
-
Strength: Trastuzumab Emtansine 100 mg per single-use vial
-
Indication: HER2-positive metastatic breast cancer (post-trastuzumab & taxane)
-
Mechanism: Monoclonal antibody + cytotoxic payload (microtubule inhibition)
-
Regulatory Status: WHO-GMP compliant; manufactured for global oncology programs
-
Packaging: Sterile lyophilized powder for reconstitution; cold-chain maintained
-
Supply Options: Single vials, multi-pack cartons, or institutional bulk lots
How to Use
UJVIRA 100 mg is administered IV by a qualified oncology professional every 3 weeks or as directed. Dose adjustments depend on body weight, liver function, and tolerability. Do not self-administer.
Safety & Monitoring
Common reactions include nausea, fatigue, thrombocytopenia, elevated liver enzymes, and infusion-related events. Monitor:
-
CBC with differential
-
LFTs & bilirubin
-
LVEF (ECHO/MUGA) prior to each cycle
Discontinue for severe hepatotoxicity, symptomatic heart failure, or grade ≥ 3 thrombocytopenia.
Contra-Indications & Precautions
-
Pregnancy / lactation (Category D) – employ reliable contraception
-
Severe hepatic impairment
-
Known hypersensitivity to trastuzumab or DM1
-
Avoid concomitant strong CYP3A4 inhibitors where possible
Drug Interactions
Inform your oncologist about all medicines, especially potent CYP3A4 modulators, anticoagulants, or other monoclonal antibodies.
Ordering & Logistics
Lead Time: 3-5 days ex-warehouse (India) | Shelf Life: ≥24 months
Shipping: Temperature-controlled, GDP-compliant; Incoterms: EXW / FCA / CIF / DDP
Documentation: COA, MSDS, Packing List, Commercial Invoice, WHO-GMP certificate, CDSCO Form-10
Quick Links for Buyers
External References
-
FDA Drug Database ↗ https://www.fda.gov/drugs/drug-approvals-and-databases/drug-database
-
National Cancer Institute on T-DM1 ↗ https://www.cancer.gov/about-cancer/treatment/drugs/breast
Why Source UJVIRA 100 mg from Us?
✔ WHO-GMP & ISO 9001 certified manufacturing
✔ Competitive ex-factory pricing for bulk & tender bids
✔ End-to-end cold-chain logistics to 180+ countries
✔ Complete regulatory dossier support for fast import clearance
Ready to place an order? Submit your purchase plan via our “Request Quote” form or email unnatipharmax@gmail.com to secure today’s best price on UJVIRA 100 mg.
Reviews
There are no reviews yet.